Early-Stage Triple-Negative Breast Cancer
Panelists discuss how triple-negative breast cancer (TNBC) is an aggressive form of breast cancer characterized by the absence of 3 key receptors: estrogen receptor, progesterone receptor, and HER2 protein. TNBC tends to grow and spread faster than other breast cancer types, presenting unique treatment challenges since common targeted therapies like hormone therapy and HER2-targeted treatments are ineffective. Standard treatment primarily relies on chemotherapy, surgery, and radiation.
Phase 3 Trial of Trilaciclib in Triple-Negative Breast Cancer Will Continue
February 13th 2024The final overall survival analysis of trilaciclib plus chemotherapy in patients with metastatic triple-negative breast cancer as part of the PRESERVE 2 trial will take place in the third quarter of 2024.
Atezolizumab/Chemo Combo Yields Survival Benefit in Metastatic TNBC
December 21st 2023Lower risk of disease progression following treatment with atezolizumab and carboplatin for metastatic triple-negative breast cancer appears to be associated with increases in tumor infiltrating lymphocytes and tumor mutational burden.
